Zuccari Guendalina, Zorzoli Alessia, Marimpietri Danilo, Brullo Chiara, Alfei Silvana
Department of Pharmacy, Section of Chemistry and Pharmaceutical and Food Technologies, University of Genoa, Viale Cembrano, 4, 16148 Genoa, Italy.
Cell Factory, IRCCS Istituto Giannina Gaslini, Via Gerolamo Gaslini 5, 16147 Genoa, Italy.
Pharmaceuticals (Basel). 2023 Mar 5;16(3):393. doi: 10.3390/ph16030393.
Neuroblastoma (NB) is a severe form of tumor occurring mainly in young children and originating from nerve cells found in the abdomen or next to the spine. NB needs more effective and safer treatments, as the chance of survival against the aggressive form of this disease are very small. Moreover, when current treatments are successful, they are often responsible for unpleasant health problems which compromise the future and life of surviving children. As reported, cationic macromolecules have previously been found to be active against bacteria as membrane disruptors by interacting with the negative constituents of the surface of cancer cells, analogously inducing depolarization and permeabilization, provoking lethal damage to the cytoplasmic membrane, and cause loss of cytoplasmic content and consequently, cell death. Here, aiming to develop new curative options for counteracting NB cells, pyrazole-loaded cationic nanoparticles (NPs) (BBB4-G4K and CB1H-P7 NPs), recently reported as antibacterial agents, were assayed against IMR 32 and SHSY 5Y NB cell lines. Particularly, while BBB4-G4K NPs demonstrated low cytotoxicity against both NB cell lines, CB1H-P7 NPs were remarkably cytotoxic against both IMR 32 and SHSY 5Y cells (IC = 0.43-0.54 µM), causing both early-stage (66-85%) and late-stage apoptosis (52-65%). Interestingly, in the nano-formulation of CB1H using P7 NPs, the anticancer effects of CB1H and P7 were increased by 54-57 and 2.5-4-times, respectively against IMR 32 cells, and by 53-61 and 1.3-2 times against SHSY 5Y cells. Additionally, based on the IC values, CB1H-P7 was also 1-12-fold more potent than fenretinide, an experimental retinoid derivative in a phase III clinical trial, with remarkable antineoplastic and chemopreventive properties. Collectively, due to these results and their good selectivity for cancer cells (selectivity indices = 2.8-3.3), CB1H-P7 NPs represent an excellent template material for developing new treatment options against NB.
神经母细胞瘤(NB)是一种主要发生在幼儿身上的严重肿瘤形式,起源于腹部或脊柱旁的神经细胞。NB需要更有效、更安全的治疗方法,因为对抗这种侵袭性疾病的存活几率非常小。此外,当目前的治疗方法取得成功时,它们往往会导致令人不适的健康问题,这些问题会影响幸存儿童的未来和生活。据报道,阳离子大分子此前已被发现作为膜破坏剂对细菌有活性,它通过与癌细胞表面的负性成分相互作用,类似地诱导去极化和通透性增加,对细胞质膜造成致命损伤,并导致细胞质内容物流失,从而导致细胞死亡。在此,为了开发对抗NB细胞的新治疗方案,最近报道的作为抗菌剂的载吡唑阳离子纳米颗粒(NPs)(BBB4-G4K和CB1H-P7 NPs)被用于检测IMR 32和SHSY 5Y NB细胞系。特别地,虽然BBB4-G4K NPs对两种NB细胞系均表现出低细胞毒性,但CB1H-P7 NPs对IMR 32和SHSY 5Y细胞均具有显著的细胞毒性(IC = 0.43 - 0.54 μM),导致早期(66 - 85%)和晚期凋亡(52 - 65%)。有趣的是,在使用P7 NPs的CB1H纳米制剂中,CB1H和P7对IMR 32细胞的抗癌作用分别提高了54 - 57倍和2.5 - 4倍,对SHSY 5Y细胞的抗癌作用分别提高了53 - 61倍和1.3 - 2倍。此外,基于IC值,CB1H-P7的效力也比芬维A胺高1 - 12倍,芬维A胺是一种正在进行III期临床试验的实验性类视黄醇衍生物,具有显著抗肿瘤和化学预防特性。总体而言,由于这些结果以及它们对癌细胞具有良好的选择性(选择性指数 = 2.8 - 3.3),CB1H-P7 NPs代表了开发对抗NB新治疗方案的优秀模板材料。